An internal Health Canada memo pertaining to universal drug coverage warns that Canadians are “sensitive to cost considerations” associated with pharmacare.
“Canadians are generally supportive of improving affordable access to prescription drugs but are also sensitive to cost considerations as government health-related expenses continue to grow, particularly in the context of Covid-19,” says the April 27 memo “Pharmacare,” according to Blacklock’s Reporter.
